Douglas Evan Godshall Shockwave Medical, Inc. (SWAV) insider trading activity

Douglas Evan Godshall is President & CEO of Shockwave Medical, Inc.. Currently has a direct ownership of 0 shares of SWAV, which is worth approximately $0. The most recent transaction as insider was on May 31, 2024, when has been sold 151,629 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

100.0% 12M change

Total Value Held $0

Douglas Evan Godshall Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 31 2024	SELL Sale (or disposition) back to the issuer	-	151,629 Reduced 100.0%	0 Common Stock
May 02 2024	SELL Payment of exercise price or tax liability	$377,302 $329.81 p/Share	1,144 Reduced 0.75%	151,629 Common Stock
Feb 20 2024	SELL Payment of exercise price or tax liability	$2,553,887 $255.67 p/Share	9,989 Reduced 6.14%	152,773 Common Stock
Feb 15 2024	SELL Open market or private sale	$2,322,900 $232.29 p/Share	10,000 Reduced 5.79%	162,762 Common Stock
Feb 15 2024	BUY Exercise of conversion of derivative security	$34,200 $3.42 p/Share	10,000 Added 5.47%	172,762 Common Stock
Feb 05 2024	SELL Payment of exercise price or tax liability	$2,067,385 $226.29 p/Share	9,136 Reduced 5.31%	162,762 Common Stock
Feb 01 2024	BUY Grant, award, or other acquisition	-	19,013 Added 9.96%	171,898 Common Stock
Jan 18 2024	SELL Payment of exercise price or tax liability	$2,232,245 $217.78 p/Share	10,250 Reduced 6.28%	152,885 Common Stock
Jan 17 2024	BUY Grant, award, or other acquisition	-	22,078 Added 11.92%	163,135 Common Stock
Jan 16 2024	SELL Open market or private sale	$2,179,300 $217.93 p/Share	10,000 Reduced 6.62%	141,057 Common Stock
Jan 16 2024	BUY Exercise of conversion of derivative security	$34,200 $3.42 p/Share	10,000 Added 6.21%	151,057 Common Stock
Jan 05 2024	SELL Open market or private sale	$2,000,500 $200.05 p/Share	10,000 Reduced 6.62%	141,057 Common Stock
Jan 05 2024	BUY Exercise of conversion of derivative security	$34,200 $3.42 p/Share	10,000 Added 6.21%	151,057 Common Stock
Dec 15 2023	SELL Open market or private sale	$943,950 $188.79 p/Share	5,000 Reduced 3.42%	141,057 Common Stock
Dec 15 2023	BUY Exercise of conversion of derivative security	$17,100 $3.42 p/Share	5,000 Added 3.31%	146,057 Common Stock
Nov 15 2023	SELL Open market or private sale	$871,900 $174.38 p/Share	5,000 Reduced 3.54%	136,057 Common Stock
Nov 15 2023	BUY Exercise of conversion of derivative security	$17,100 $3.42 p/Share	5,000 Added 3.42%	141,057 Common Stock
Nov 02 2023	SELL Payment of exercise price or tax liability	$126,729 $214.07 p/Share	592 Reduced 0.42%	141,057 Common Stock
Oct 16 2023	SELL Open market or private sale	$1,997,100 $199.71 p/Share	10,000 Reduced 6.59%	141,649 Common Stock
Oct 16 2023	BUY Exercise of conversion of derivative security	$34,200 $3.42 p/Share	10,000 Added 6.19%	151,649 Common Stock
Sep 15 2023	SELL Open market or private sale	$2,126,200 $212.62 p/Share	10,000 Reduced 6.59%	141,649 Common Stock
Sep 15 2023	BUY Exercise of conversion of derivative security	$34,200 $3.42 p/Share	10,000 Added 6.19%	151,649 Common Stock
Aug 24 2023	SELL Open market or private sale	$2,129,500 $212.95 p/Share	10,000 Reduced 6.59%	141,649 Common Stock
Aug 24 2023	BUY Exercise of conversion of derivative security	$34,200 $3.42 p/Share	10,000 Added 6.19%	151,649 Common Stock
Aug 03 2023	SELL Payment of exercise price or tax liability	$153,561 $250.1 p/Share	614 Reduced 0.43%	141,649 Common Stock

Also insider at

EYPT

EyePoint Pharmaceuticals, Inc. Healthcare

DEG